Assessment of quality of life enjoyment and satisfaction questionnaire-short form responder thresholds in generalized anxiety disorder and bipolar disorder studies

International Clinical Psychopharmacology

Volumn 26, Issue 3, 2011, Pages 121-129

  Wyrwich, Kathleen W ^a   Harnam, Neesha ^a   Revicki, Dennis A ^a   Locklear, Julie C ^b   Svedsater, Henrik ^d   Endicott, Jean ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

bipolar disorder; generalized anxiety disorder; minimal important difference; patient reported outcomes; quality of life; responder analyses

Indexed keywords

BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; GENERALIZED ANXIETY DISORDER; HUMAN; MENTAL HEALTH; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE SHORT FORM; QUESTIONNAIRE; REVIEW;

ANXIETY DISORDERS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; PERSONAL SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 79954718186     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283427cd7     Document Type: Review

References (52)

1. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press.
2. Atkinson S, Khan A, Joyce M, Eggens I, Baldytcheva I, Brecher M (2008). Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetia-pine XR) monotherapy in patients with generalised anxiety disorder. Int J Neuropsychopharmacol 11 (Suppl 1):277.
3. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsycho-pharmacol 13:305-320.
4. Barger SD, Sydeman SJ (2005). Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder? J Affect Disord 88:87-91. (Pubitemid 41160418)
5. Begley CE, Annegers JF, Swann AC, Lewis C, Coan S, Schnapp WB, et al. (2001). The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19 (5 Pt 1):483-495. (Pubitemid 32488750)
6. Bose A, Korotzer A, Gommoll C, Li D (2008). Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety 25:854-861.
7. Chand PK, Mattoo SK, Sharan P (2004). Quality of life and its correlates in patients with bipolar disorder stabilized on lithium prophylaxis. Psychiatry Clin Neurosci 58:311-318. (Pubitemid 38859014)
8. Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T (2005). Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand 111:429-435. (Pubitemid 40776287)
9. Danovitch I, Endicott J (2008). Quality of life measures. In: Rush AJ Jr, First MB, Blacker D, editors. Handbook of psychiatric measures. 2nd ed. Washington, DC: American Psychiatric Publishing; pp. 125-139.
10. Davidson JR, Bose A, Korotzer A, Zheng H (2004). Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234-240. (Pubitemid 39014143)
11. Demyttenaere K, Andersen HF, Reines EH (2008). Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol 23:276-286.
12. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29:321-326. (Pubitemid 23311543)
13. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W; The BOLDER Study Group (2007). A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 22:29-37. (Pubitemid 44950765)
14. Endicott J, Paulsson B, Gustafsson U, Schioler H, Hassan M (2008). Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 111:306-319.
15. ESEMeD/MHEDEA 2000 Investigators (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 109 (Suppl 1):21-27.
16. Fajutrao L, Locklear J, Priaulx J, Heyes A (2009). A systematic review of the evidence of the burden of bipolar disorder in Europe. Clin Pract Epidemiol Ment Health 5:3.
17. Faravelli C, Guerrini Degl'Innocenti B, Giardinelli L (1989). Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 79:308-312. (Pubitemid 19110369)
18. Food and Drug Administration (2009). Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 74:65132-65133.
19. Gelfin Y, Gorfine M, Lerer B (1998). Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am J Psych 155:290-292. (Pubitemid 28074298)
20. Goodman WK, Bose A, Wang Q (2005). Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161-167. (Pubitemid 41039938)
21. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, et al. (2005). Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 35:1747-1759. (Pubitemid 41672353)
22. Guy W (1976). ECDEU assessment manual for psychopharmacology - revised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
23. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, et al. (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo- and active-controlled trial. Int Clin Psychopharmacol 22:167-174. (Pubitemid 46559873)
24. Henning ER, Turk CL, Mennin DS, Fresco DM, Heimberg RG (2007). Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24:342-349. (Pubitemid 47403484)
25. Hoyer J, Becker ES, Margraf J (2002). Generalized anxiety disorder and clinical worry episodes in young women. Psychol Med 32:1227-1237. (Pubitemid 35243980)
26. Kessler RC, Wittchen HU (2002). Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry 63 (Suppl 8):4-10. (Pubitemid 34535251)
27. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19. (Pubitemid 24028993)
28. Kessler RC, DuPont RL, Berglund P, Wittchen HU (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923.
29. Kessler RC, Keller MB, Wittchen H (2001). The epidemiology of generalized anxiety disorder. In: Brawman-Mintzer O, editor. The psychiatric clinics of North America: generalized anxiety disorder. Philadelphia, PA: W.B. Saunders; pp. 19-40.
30. Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D (2003). Costs of bipolar disorder. Pharmacoeconomics 21:601-622. (Pubitemid 36808214)
31. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, et al. (2007). Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 9:100-107. (Pubitemid 46607463)
32. Massion AO, Warshaw MG, Keller MB (1993). Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry 150:600-607. (Pubitemid 23109929)
33. Merideth C, Cutler A, Neijber A, She F, Eriksson H (2008). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) mono-therapy in the treatment of generalised anxiety disorder. Eur Neuropsycho-pharmacol 18 (Suppl 4):S499.
34. Mick E, Faraone SV, Spencer T, Zhang HF, Biederman J (2008). Assessing the validity of the quality of life enjoyment and satisfaction questionnaire short form in adults with ADHD. J Atten Dis 11:504-509.
35. Newnham EA, Harwood KE, Page AC (2007). Evaluating the clinical significance of responses by psychiatric inpatients to the mental health subscales of the SF-36. J Affect Disord 98:91-97. (Pubitemid 46048904)
36. Ozen S, Sir A (2004). Frequency of PTSD in a group of search and rescue workers two months after 2003 Bingol (Turkey) earthquake. J Nerv Ment Dis 192:573-575. (Pubitemid 39095646)
37. Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, et al. (2008). Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 42:1042-1049.
38. Rabkin J, Wagner G, Griffin KW (2000). Quality of life measures. In: Rush AJ, Pincus HA, First MB editors. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association Press; pp. 135-150.
39. Rapaport MH, Wolkow RM, Clary CM (1998). Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Psychopharmcol Bull 34:183-189.
40. Rapaport MH, Endicott J, Clary CM (2002). PTSD and Quality of Life: Results across 64 weeks of sertraline treatment. J Clin Psychiatry 63:59-65. (Pubitemid 34113489)
41. Rapaport MH, Clary C, Fayyad R, Endicott J (2005). Quality-of-Life impairment in depressive and anxiety disorders. Am J Psychiatry 162:1171-1178. (Pubitemid 40770701)
42. Revicki DA, Hanlon J, Martin S, Gyulai L, Nassir Ghaemi S, Lynch F, et al. (2005). Patient-based utilities for bipolar disorder-related health states. J Affect Disord 87:203-210. (Pubitemid 41039942)
43. Revicki DA, Brandenburg N, Matza L, Hornbrook MC, Feeny D (2008a). Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Qual Life Res 17:1285-1294.
44. Revicki DA, Hays RD, Cella D, Sloan J (2008b). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61:102-109.
45. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J (2005). Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res 14:1693-1703. (Pubitemid 40978478)
46. Rynn MA, Russell JM, Erickson J, Detke M, Ball SG, Dinkel J, et al. (2007). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25:182-189.
47. Schechter D, Endicott J, Nee J (2007). Quality of life of 'normal' controls: association with lifetime history of mental illness. Psychiatry Res 152:45-54. (Pubitemid 47030679)
48. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600-609. (Pubitemid 44772737)
49. Wittchen HU (2002). Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162-171.
50. Wittchen H-U, Carter RM, Pfister H, Montgomery SA, Kessler RC (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15:319-328.
51. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 37:469-478.
52. Wyrwich K, Harnam N, Revicki DA, Locklear JC, Svedsater H, Endicott J (2009). Assessing health-related quality of life in generalized anxiety disorder using the Quality of Life Enjoyment and Satisfaction Questionnaire. Int Clin Psychopharmacol 24:289-295.